CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.79B, above the global median of $1.18B
- FinancialsAltman Z-Score 1.88: grey zone
- Interpretations10 currently firing — 10
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.79BUSDvs all stocks (USD)
Revenue (TTM)
335.41MUSDvs all stocks (USD)
Profit Margin
-5.12%vs Biotechnology peers
Beta
0.8500xvs all stocks
52-Week Change
21.66%vs all stocks
Market Capitalization
1.79BUSDvs all stocks (USD)
Enterprise Value
1.83BUSDvs all stocks (USD)
Forward P/E
23.33xvs Biotechnology peers
Price to Sales (TTM)
4.95xvs Biotechnology peers
Enterprise to Revenue
5.45xvs Biotechnology peers
Enterprise to EBITDA
37.46xvs Biotechnology peers
Gross Margin
86.41%vs Biotechnology peers
Profit Margin
-5.12%vs Biotechnology peers
Operating Margin
5.62%vs Biotechnology peers
Return on Assets (TTM)
6.13%vs Biotechnology peers
Revenue (TTM)
335.41MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.99USDUpdated Sep 28, 2026Quarterly Revenue Growth
28.70%vs Biotechnology peers
Gross Profit (TTM)
290.38MUSDvs all stocks (USD)
EBITDA (TTM)
54.67MUSDvs all stocks (USD)
Net Income (TTM)
-17.16MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
28.74%vs Biotechnology peers
Operating Cash Flow (TTM)
56.61MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
52.45MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
291.85MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
42.57MUSDFY2025 · Dec 31, 2025Gross Profit
249.28MUSDFY2025 · Dec 31, 2025Operating Income
24.90MUSDvs all stocks (USD)
Pre-tax Income
554.00KUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
554.00KUSDFY2025 · Dec 31, 2025EBIT
29.64MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
42.33MUSDFY2025 · Dec 31, 2025Research & Development
31.16MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
182.37MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
4.74MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
29.08MUSDFY2025 · Dec 31, 2025EPS (Basic)
0.00USDFY2025 · Dec 31, 2025EPS (Diluted)
0.00USDFY2025 · Dec 31, 2025Basic Shares Outstanding
160.43MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
160.43MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
554.00KUSDFY2025 · Dec 31, 2025Operating Cash Flow
11.03MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
115.06MUSDFY2025 · Dec 31, 2025Interest Paid
27.12MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
554.00KUSDFY2025 · Dec 31, 2025Depreciation & Amortization
12.69MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
0.00USDFY2025 · Dec 31, 2025Stock-based Compensation
22.37MUSDFY2025 · Dec 31, 2025Other Non-cash Items
3.37MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-10.63MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-69.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-17.25MUSDFY2025 · Dec 31, 2025Purchase of Investments
0.00USDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
0.00USDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Common Stock Repurchase
-10.88MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.71MUSDFY2025 · Dec 31, 2025Shares Outstanding
173.59MSharesUpdated Sep 28, 2026Float Shares
176.00MSharesUpdated Sep 28, 2026Shares Short
8.06MSharesUpdated Sep 28, 2026Short Ratio
5.10daysvs all stocks
Short % of Shares Outstanding
4.57%vs all stocks
% Held by Insiders
3.06%vs all stocks
% Held by Institutions
60.12%vs all stocks
Total Cash (MRQ)
121.75MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.6680USDUpdated Sep 28, 2026Total Debt (MRQ)
289.44MUSDvs all stocks (USD)
Current Ratio (MRQ)
1.45xvs Biotechnology peers
Book Value per Share (MRQ)
-0.0560USDUpdated Sep 28, 2026Total Assets
383.53MUSDvs all stocks (USD)
Total Current Assets
240.31MUSDFY2025 · Dec 31, 2025Total Liabilities
369.84MUSDFY2025 · Dec 31, 2025Total Non-current Assets
143.21MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
260.26MUSDFY2025 · Dec 31, 2025Total Current Liabilities
109.57MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
111.04MUSDFY2025 · Dec 31, 2025Accounts Receivable
51.05MUSDFY2025 · Dec 31, 2025Inventory
68.67MUSDFY2025 · Dec 31, 2025Accounts Payable
3.08MUSDFY2025 · Dec 31, 2025Short-term Debt
6.23MUSDFY2025 · Dec 31, 2025Other Current Liabilities
4.89MUSDFY2025 · Dec 31, 2025Long-term Debt
251.87MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
8.40MUSDFY2025 · Dec 31, 2025Common Stock (Book)
17.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-671.31MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
13.69MUSDvs all stocks (USD)
52-Week Low
5.25USDUpdated Sep 28, 202652-Week High
10.08USDUpdated Sep 28, 202652-Week Change
21.66%vs all stocks
Beta
0.8500xvs all stocks
50-Day MA
8.36USDUpdated Sep 28, 2026200-Day MA
7.13USDUpdated Sep 28, 2026Avg 10-Day Volume
2.21MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.78MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-0.1000USDUpdated Sep 28, 202610 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
Elevated ROE With High Debt-to-Equity and Equity Multiplier
Return on equity reads high on a balance sheet carrying a lot of debt against that equity.
Reads
Diagnostic
Depreciation-Heavy Reported Profit
It reports a profit, and much of the gap to cash is depreciation rather than earnings.
Reads
Diagnostic
Earnings Growth With Heavy Accrual Component
It reports a profit, with depreciation heavy in the cash bridge and receivables rising.
Reads
Cash-Backed Growth Configuration
Revenue has grown steadily, and the cash arriving matches reported profit.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Where is this company structurally exposed?
Elevated Leverage on Three Denominators
Debt sits high against its equity, its assets, and its cash flow.
Reads
SBC-to-Net-Income Elevated, SBC-to-Revenue Elevated, And Diluted Share Count Growing (6Y CAGR)
Pay in shares is large next to its revenue and its profit, and the share count keeps rising.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.86Profit Margin: -0.05
Financial Health
Altman Z-Score 1.88: grey zoneSignificant
Altman Z-Score: 1.88
High structural barrier to entryNotable
Barrier to Entry: 1.49
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.79B, above the global median of $1.18BNotable
Market cap (USD): 1,792,208,607Global Median: 1,180,223,658.953
Levered free cash flow is $52.45M, above the global median of $18.73MNotable
Levered free cash flow (USD): 52,450,124Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Zenas BioPharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jafron Biomedical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Eris Lifesciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Vir Biotechnology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cohance Lifesciences Limited
Tier 1ProductionApproval-Gated PipelineRule
Wedge Industrial Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Rhodiola Pharmaceutical Holding Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Olymvax Biopharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
PolyPeptide Group AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
Alivus Life Sciences Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Travere Therapeutics Inc.
7 interpretationsElevated Leverage on Three DenominatorsElevated ROE With High Debt-to-Equity and Equity MultiplierRevenue Growing With Receivables GrowingEarnings Growth With Heavy Accrual ComponentIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedDepreciation-Heavy Reported Profit
Smartfit Escola de Ginástica e Dança S.A.
5 interpretationsCash-Backed Growth ConfigurationElevated Leverage on Three DenominatorsElevated ROE With High Debt-to-Equity and Equity MultiplierRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue Growth
Beigene Ltd.
5 interpretationsCash-Backed Growth ConfigurationRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated